NIH/3T3 cells transformed with the activated erbB-2 oncogene can be phenotypically reverted by a kinase deficient, dominant negative erbB-2 variant.

NIH/3T3 cells transformed with the activated erbB-2 oncogene can be phenotypically reverted by a kinase deficient, dominant negative erbB-2 variant.

Item
http://www.wikidata.org/entity/Q42833659
ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner.Construction of a computable cell proliferation network focused on non-diseased lung cells.Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trialHER2/neu: mechanisms of dimerization/oligomerization.The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisTargeting the function of the HER2 oncogene in human cancer therapeutics.Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells.Inhibitory role of alpha 6 beta 4-associated erbB-2 and phosphoinositide 3-kinase in keratinocyte haptotactic migration dependent on alpha 3 beta 1 integrin.Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2.An apoptosis-inducing isoform of neu differentiation factor (NDF) identified using a novel screen for dominant, apoptosis-inducing genesProtection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA.Oncogenic Neu/ErbB-2 increases ets, AP-1, and NF-kappaB-dependent gene expression, and inhibiting ets activation blocks Neu-mediated cellular transformation.A full biological response to autoantibodies in Graves' disease requires a disulfide-bonded loop in the thyrotropin receptor N terminus homologous to a laminin epidermal growth factor-like domain.Intratumoral administration of an adenovirus expressing a kinase dead form of ErbB-2 inhibits tumor growth.
P2860

NIH/3T3 cells transformed with the activated erbB-2 oncogene can be phenotypically reverted by a kinase deficient, dominant negative erbB-2 variant.

Item
http://www.wikidata.org/entity/Q42833659
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
NIH/3T3 cells transformed with ...... inant negative erbB-2 variant.
@en
NIH/3T3 cells transformed with ...... inant negative erbB-2 variant.
@nl
type
label
NIH/3T3 cells transformed with ...... inant negative erbB-2 variant.
@en
NIH/3T3 cells transformed with ...... inant negative erbB-2 variant.
@nl
prefLabel
NIH/3T3 cells transformed with ...... inant negative erbB-2 variant.
@en
NIH/3T3 cells transformed with ...... inant negative erbB-2 variant.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P577
P698
P356
P1433
P1476
NIH/3T3 cells transformed with ...... inant negative erbB-2 variant.
@en
P2093
P304
P31
P356
10.1016/0303-7207(94)90029-9
P433
P478
P577
P698